Ardelyx vs CorMedix
ARDX and CRMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDX and CRMD compare
Ardelyx is the larger company, worth 2.2 times as much as CorMedix ($792M against $364M).
CorMedix grew revenue faster over the last twelve months (281% versus 16.8% for Ardelyx).
CorMedix keeps more of each dollar of sales as profit, with a net margin of 40.5% compared with −12.4% at Ardelyx.
CorMedix scores higher on the StockData Score (13 against 9 for Ardelyx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDX | CRMD |
|---|---|---|
| Size and price | ||
| Market cap | $792M | $364M |
| Share price | $3.18 | $4.67 |
| Change, 1 year | −45.7% | −58.5% |
| Change, 5 years | 256% | −7.9% |
| Beta (5Y) | 1.09 | 0.49 |
| Employees | 489 | 191 |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 3 | 3 |
| Performance score | 3 | 4 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× | 0.8× (better) |
| P/B | 5.3× | 0.8× (better) |
| EV/EBITDA | – | 0.5× |
| P/FCF | – | 1.5× |
| FCF yield | −2.3% | 68.8% (better) |
| Fair value | $7.61 | – |
| Margin of safety | 58.2% | – |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 281% (better) |
| Revenue growth, 5Y average | 122% | 320% (better) |
| Net income growth (TTM) | – | 266% |
| Profitability | ||
| Gross margin | 94.4% (better) | 82.8% |
| Operating margin | −7.9% | 47.0% (better) |
| Net margin | −12.4% | 40.5% (better) |
| FCF margin | −4.0% | 54.2% (better) |
| Return on equity | −38.6% | 54.9% (better) |
| Return on invested capital | – | 171% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1.6× | – |
| Current ratio | 3.34 (better) | 2.56 |
| Altman Z-score | −0.10 | 2.01 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.28% |
| Shareholder yield | 0.00% (better) | −0.28% |
| Ownership | ||
| Held by institutions | 71.2% | 56.5% |
| Held by insiders | 6.9% | 3.3% |
| Insider net buying, 12 months | −$1.9M | −$1.6M (better) |
| Short interest, % of float | 12.6% | 18.8% |
Go deeper
- ARDX stock overview
- ARDX income statement
- ARDX valuation and score
- CRMD stock overview
- CRMD income statement
- CRMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.